Here’s what’s most reliably established about the latest direction of research and treatment for glycogen storage disease type II (GSD II), also called Pompe disease:
Enzyme replacement therapy (ERT) remains a core disease-modifying approach, and evidence has long focused on how effectiveness varies by subtype (infantile vs juvenile/adult-onset) and by measurable functional outcomes.[1][2]
A key practical milestone in the last several years has been the regulatory authorization of newer ERTs (e.g., avalglucosidase alfa and later cipaglucosidase alfa), which expanded options in Europe and the US and support broader access across age groups (context: EU availability details are described in reference summaries).[4]
Because late-onset GSD II shows progression in muscle function over time and can respond variably to ERT, many studies emphasize:
Clinical overviews also stress that Pompe disease has a continuous spectrum—infantile-onset tends to be the most severe (including major cardiac involvement early), while late-onset disease more often centers on progressive skeletal muscle dysfunction with different prognosis.[5]
Right now, I can summarize what the medical literature and regulatory context indicate, but I don’t have enough browsing capacity in this message to reliably pull this week’s headlines. If you tell me which you mean, I’ll tailor the update:
Reply with your preference (and your country if relevant), and I’ll format a “latest updates” digest.
Medical and health news service that features the most comprehensive coverage in the fields of neuroscience, cardiology, cancer, HIV/AIDS, psychology, psychiatry, dentistry, genetics, diseases and conditions, medications and more.
medicalxpress.comGlycogen storage disease type II, also known as Pompe disease, is a rare and progressive neuromuscular disorder inherited in an autosomal recessive manner. This disease results from a deficiency of the enzyme acid α-glucosidase (GAA), causing impairment in the degradation of glycogen within the lyso …
pubmed.ncbi.nlm.nih.govMethods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II.
patents.google.comGlycogen storage disease type II (GSDII) is an autosomal recessive lysosomal disorder caused by mutations in the gene encoding alpha-glucosidase (GAA). The disease can be clinically classified into three types: a severe infantile form, a juvenile ...
pmc.ncbi.nlm.nih.govGlycogen storage disease type II (GSD II) is characterized clinically by severe muscle weakness, moderate hepatomegaly, and substantial cardiac enlargement in an infant who appeared "healthy" at birth (see page 622). Hypotonia and cardiomegaly are so extreme that they cannot be missed. This ease of...
jamanetwork.comClinical and genetic mutation analysis was performed on 5 infantile glycogen storage disease type II children in Chinese mainland. Clinical data of 5 children with infantile-type glycogen storage disease type II due to the acidic α-glucosidase (GAA) ...
pmc.ncbi.nlm.nih.govNews and Articles Updates of interest to the GSD community Latest News & Articles Past News & Articles
agsdus.orgGlycogen storage disease type II has a broad continuous clinical spectrum in terms of onset, involvement of organs and life expectancy. Infantile onset is the most severe form, presenting with prominent cardiomyopathy, hypotonia, hepatomegaly and ...
pmc.ncbi.nlm.nih.govGlycogen storage disease type II (GSDII) is an autosomal recessive lysosomal disorder caused by mutations in the gene encoding alpha-glucosidase (GAA). The disease can be clinically classified into three types: a severe infantile form, a juvenile and an adultonset form. Cases with juvenile or adult …
pubmed.ncbi.nlm.nih.gov